← All trials
NCT04897594
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 18, 2021
- Primary completion
- Sep 30, 2022
- Completion date
- Nov 30, 2022
- First posted
- May 21, 2021
- Last posted
- Sep 16, 2021
- Enrollment
- 60
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Terns, Inc.Lead sponsor
- Terns, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.